JP2012515724A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012515724A5 JP2012515724A5 JP2011546451A JP2011546451A JP2012515724A5 JP 2012515724 A5 JP2012515724 A5 JP 2012515724A5 JP 2011546451 A JP2011546451 A JP 2011546451A JP 2011546451 A JP2011546451 A JP 2011546451A JP 2012515724 A5 JP2012515724 A5 JP 2012515724A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- fluoro
- cycloalkyl
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 amino, substituted amino, carboxyl Chemical group 0.000 claims 42
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 125000000547 substituted alkyl group Chemical group 0.000 claims 20
- 125000000623 heterocyclic group Chemical group 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 125000002252 acyl group Chemical group 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 230000002757 inflammatory effect Effects 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000004442 acylamino group Chemical group 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 5
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 201000004624 Dermatitis Diseases 0.000 claims 4
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- TVNUWQIRTYYTNN-UHFFFAOYSA-N 5-fluoro-4-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-6-phenylpyrimidine-2,4-diamine Chemical compound C1(=CC=CC=C1)C1=C(C(=NC(=N1)N)NC1CC(N(C(C1)(C)C)C)(C)C)F TVNUWQIRTYYTNN-UHFFFAOYSA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000030090 Acute Disease Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 208000022461 Glomerular disease Diseases 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010022680 Intestinal ischaemia Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000013901 Nephropathies and tubular disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000031709 Skin Manifestations Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 206010044541 Traumatic shock Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 208000024248 Vascular System injury Diseases 0.000 claims 2
- 208000012339 Vascular injury Diseases 0.000 claims 2
- 206010053648 Vascular occlusion Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 230000002491 angiogenic effect Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 208000037976 chronic inflammation Diseases 0.000 claims 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000001875 irritant dermatitis Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 206010023332 keratitis Diseases 0.000 claims 2
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 201000010901 lateral sclerosis Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000020763 muscle atrophy Effects 0.000 claims 2
- 201000000585 muscular atrophy Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 208000021331 vascular occlusion disease Diseases 0.000 claims 2
- SYYSBZOSEAUMEY-UHFFFAOYSA-N 1,1,1-trifluoro-2-$l^{1}-sulfanylethane Chemical group FC(F)(F)C[S] SYYSBZOSEAUMEY-UHFFFAOYSA-N 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- BFMGOJBQXYYXLG-UHFFFAOYSA-N 2-n-[3-(2,5-dimethylpyrrol-1-yl)-4-(2-morpholin-4-ylethoxy)phenyl]-5-fluoro-4-n-(1,2,2,6,6-pentamethylpiperidin-4-yl)pyrimidine-2,4-diamine Chemical compound C1C(C)(C)N(C)C(C)(C)CC1NC1=NC(NC=2C=C(C(OCCN3CCOCC3)=CC=2)N2C(=CC=C2C)C)=NC=C1F BFMGOJBQXYYXLG-UHFFFAOYSA-N 0.000 claims 1
- YKFGBWVAVVOOQP-UHFFFAOYSA-N 2-n-[3-(2,5-dimethylpyrrol-1-yl)-4-(2-morpholin-4-ylethoxy)phenyl]-5-fluoro-4-n-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine Chemical compound CC1=CC=C(C)N1C1=CC(NC=2N=C(NC3CC(C)(C)NC(C)(C)C3)C(F)=CN=2)=CC=C1OCCN1CCOCC1 YKFGBWVAVVOOQP-UHFFFAOYSA-N 0.000 claims 1
- RQHZHEIDLQGEFL-UHFFFAOYSA-N 2-n-[3-(2,5-dimethylpyrrol-1-yl)-4-(2-pyrrolidin-1-ylethoxy)phenyl]-5-fluoro-4-n-(1,2,2,6,6-pentamethylpiperidin-4-yl)pyrimidine-2,4-diamine Chemical compound C1C(C)(C)N(C)C(C)(C)CC1NC1=NC(NC=2C=C(C(OCCN3CCCC3)=CC=2)N2C(=CC=C2C)C)=NC=C1F RQHZHEIDLQGEFL-UHFFFAOYSA-N 0.000 claims 1
- QIPDYHFWFMMPQM-UHFFFAOYSA-N 2-n-[3-(2,5-dimethylpyrrol-1-yl)-4-(2-pyrrolidin-1-ylethoxy)phenyl]-5-fluoro-4-n-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine Chemical compound CC1=CC=C(C)N1C1=CC(NC=2N=C(NC3CC(C)(C)NC(C)(C)C3)C(F)=CN=2)=CC=C1OCCN1CCCC1 QIPDYHFWFMMPQM-UHFFFAOYSA-N 0.000 claims 1
- PCJSQXQRMJJBBS-UHFFFAOYSA-N 4-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-5-phenylpyrimidine-2,4-diamine Chemical compound C1(=CC=CC=C1)C=1C(=NC(=NC=1)N)NC1CC(N(C(C1)(C)C)C)(C)C PCJSQXQRMJJBBS-UHFFFAOYSA-N 0.000 claims 1
- DFVSXLDAJLVVLH-UHFFFAOYSA-N 5-fluoro-2-n-[3-methoxy-5-(2-morpholin-4-ylethoxy)phenyl]-4-n-(1,2,2,6,6-pentamethylpiperidin-4-yl)pyrimidine-2,4-diamine Chemical compound C=1C(OCCN2CCOCC2)=CC(OC)=CC=1NC(N=1)=NC=C(F)C=1NC1CC(C)(C)N(C)C(C)(C)C1 DFVSXLDAJLVVLH-UHFFFAOYSA-N 0.000 claims 1
- JAUBLXVJBSZVSH-UHFFFAOYSA-N 5-fluoro-2-n-[3-methoxy-5-(2-morpholin-4-ylethoxy)phenyl]-4-n-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine Chemical compound C=1C(OCCN2CCOCC2)=CC(OC)=CC=1NC(N=1)=NC=C(F)C=1NC1CC(C)(C)NC(C)(C)C1 JAUBLXVJBSZVSH-UHFFFAOYSA-N 0.000 claims 1
- VTKJXOMDTPRGOL-UHFFFAOYSA-N 5-fluoro-2-n-[3-methoxy-5-(2-pyrrol-1-ylethoxy)phenyl]-4-n-(1,2,2,6,6-pentamethylpiperidin-4-yl)pyrimidine-2,4-diamine Chemical compound C=1C(OCCN2C=CC=C2)=CC(OC)=CC=1NC(N=1)=NC=C(F)C=1NC1CC(C)(C)N(C)C(C)(C)C1 VTKJXOMDTPRGOL-UHFFFAOYSA-N 0.000 claims 1
- BUUNPQCCBUNUSR-UHFFFAOYSA-N 5-fluoro-2-n-[3-methoxy-5-(2-pyrrol-1-ylethoxy)phenyl]-4-n-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine Chemical compound C=1C(OCCN2C=CC=C2)=CC(OC)=CC=1NC(N=1)=NC=C(F)C=1NC1CC(C)(C)NC(C)(C)C1 BUUNPQCCBUNUSR-UHFFFAOYSA-N 0.000 claims 1
- HTGWTCFYVDIVPK-UHFFFAOYSA-N 5-fluoro-2-n-[3-methoxy-5-(2-pyrrolidin-1-ylethoxy)phenyl]-4-n-(1,2,2,6,6-pentamethylpiperidin-4-yl)pyrimidine-2,4-diamine Chemical compound C=1C(OCCN2CCCC2)=CC(OC)=CC=1NC(N=1)=NC=C(F)C=1NC1CC(C)(C)N(C)C(C)(C)C1 HTGWTCFYVDIVPK-UHFFFAOYSA-N 0.000 claims 1
- BFCNQMNRCLSWEV-UHFFFAOYSA-N 5-fluoro-2-n-[3-methoxy-5-(2-pyrrolidin-1-ylethoxy)phenyl]-4-n-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidine-2,4-diamine Chemical compound C=1C(OCCN2CCCC2)=CC(OC)=CC=1NC(N=1)=NC=C(F)C=1NC1CC(C)(C)NC(C)(C)C1 BFCNQMNRCLSWEV-UHFFFAOYSA-N 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14627309P | 2009-01-21 | 2009-01-21 | |
| US61/146,273 | 2009-01-21 | ||
| US26416509P | 2009-11-24 | 2009-11-24 | |
| US61/264,165 | 2009-11-24 | ||
| PCT/US2010/021662 WO2010090875A1 (en) | 2009-01-21 | 2010-01-21 | Derivatives of n2-(3-pyridil or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015018931A Division JP2015110629A (ja) | 2009-01-21 | 2015-02-03 | 炎症性疾患、自己免疫疾患または増殖性疾患の治療に有用なｎ２−（３−ピリジルまたはフェニル）−ｎ４−（４−ピペリジル）−２，４−ピリミジンジアミン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012515724A JP2012515724A (ja) | 2012-07-12 |
| JP2012515724A5 true JP2012515724A5 (https=) | 2013-03-07 |
| JP5781943B2 JP5781943B2 (ja) | 2015-09-24 |
Family
ID=42272042
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011546451A Expired - Fee Related JP5781943B2 (ja) | 2009-01-21 | 2010-01-21 | 炎症性疾患、自己免疫疾患または増殖性疾患の治療に有用なｎ２−（３−ピリジルまたはフェニル）−ｎ４−（４−ピペリジル）−２，４−ピリミジンジアミン誘導体 |
| JP2015018931A Withdrawn JP2015110629A (ja) | 2009-01-21 | 2015-02-03 | 炎症性疾患、自己免疫疾患または増殖性疾患の治療に有用なｎ２−（３−ピリジルまたはフェニル）−ｎ４−（４−ピペリジル）−２，４−ピリミジンジアミン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015018931A Withdrawn JP2015110629A (ja) | 2009-01-21 | 2015-02-03 | 炎症性疾患、自己免疫疾患または増殖性疾患の治療に有用なｎ２−（３−ピリジルまたはフェニル）−ｎ４−（４−ピペリジル）−２，４−ピリミジンジアミン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8377924B2 (https=) |
| EP (1) | EP2389373B1 (https=) |
| JP (2) | JP5781943B2 (https=) |
| CA (1) | CA2749837C (https=) |
| ES (1) | ES2635504T3 (https=) |
| WO (1) | WO2010090875A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE506953T1 (de) * | 2003-08-07 | 2011-05-15 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
| EP2507227B1 (en) * | 2009-12-01 | 2014-10-08 | Rigel Pharmaceuticals, Inc. | Tetrazolones as protein kinase c inhibitors and uses thereof |
| JP6035238B2 (ja) * | 2010-07-21 | 2016-11-30 | ライジェル ファーマシューティカルズ， インコーポレイテッド | プロテインキナーゼｃ阻害剤およびその使用 |
| AU2011328673B2 (en) * | 2010-11-09 | 2016-02-25 | Betta Pharmaceuticals Co., Ltd | Compound for increasing kinase active and application thereof |
| US9139534B2 (en) * | 2011-04-22 | 2015-09-22 | Signal Pharmaceuticals, Llc | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith |
| ES2658395T3 (es) | 2012-04-04 | 2018-03-09 | Rigel Pharmaceuticals, Inc. | Inhibidores de proteína cinasa C y usos de los mismos |
| EP2928891B1 (en) | 2012-12-04 | 2019-02-20 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| CA2904610A1 (en) | 2013-03-14 | 2014-09-25 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| US9556126B2 (en) | 2013-12-20 | 2017-01-31 | Signal Pharmaceuticals, Llc | Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith |
| NZ715903A (en) | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
| WO2015148867A1 (en) | 2014-03-28 | 2015-10-01 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| WO2016060963A1 (en) | 2014-10-14 | 2016-04-21 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| US9513297B2 (en) | 2014-12-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Methods for measurement of inhibition of c-Jun N-terminal kinase in skin |
| CN107108524A (zh) | 2014-12-16 | 2017-08-29 | 西格诺药品有限公司 | 2‑(叔丁基氨基)‑4‑((1r,3r,4r)‑3‑羟基‑4‑甲基环己基氨基)‑嘧啶‑5‑甲酰胺的配制物 |
| EP3250557B1 (en) | 2015-01-29 | 2024-11-20 | Signal Pharmaceuticals, LLC | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| ES2854703T3 (es) * | 2015-07-09 | 2021-09-22 | Merck Patent Gmbh | Compuestos de heteroarilo como inhibidores de BTK y usos de los mismos |
| CN107922287B (zh) | 2015-07-24 | 2021-04-09 | 细胞基因公司 | 合成(1r,2r,5r)-5-氨基-2-甲基环己醇盐酸盐的方法和其中可用的中间体 |
| JP2018527362A (ja) | 2015-09-11 | 2018-09-20 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | 置換されたヘテロアリール化合物および使用方法 |
| US20180305318A1 (en) | 2015-10-30 | 2018-10-25 | Bioventures, Llc | Inhibitors of oxidized low-density lipoprotein receptor 1 and methods of use thereof |
| CN110621316B (zh) | 2017-04-21 | 2024-01-26 | Epizyme股份有限公司 | 用ehmt2抑制剂进行的组合疗法 |
| AU2018266911C1 (en) | 2017-05-12 | 2022-10-20 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2018218051A1 (en) | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10246439B2 (en) | 2017-05-25 | 2019-04-02 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2018218042A1 (en) | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10597382B2 (en) | 2017-08-28 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| CA3079260A1 (en) * | 2017-10-17 | 2019-04-25 | Epizyme, Inc. | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and derivatives thereof |
| WO2019099311A1 (en) | 2017-11-19 | 2019-05-23 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| WO2019213239A1 (en) | 2018-05-02 | 2019-11-07 | Enanta Pharmaceuticals Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| ES3004523T3 (en) | 2018-05-02 | 2025-03-12 | Enanta Pharm Inc | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020041417A1 (en) | 2018-08-22 | 2020-02-27 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020106707A1 (en) | 2018-11-19 | 2020-05-28 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US11466033B2 (en) | 2019-03-25 | 2022-10-11 | Enanta Pharmaceuticals, Inc. | Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors |
| WO2022147622A1 (en) * | 2021-01-07 | 2022-07-14 | Ontario Institute For Cancer Research (Oicr) | Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof |
| EP4401735A4 (en) * | 2021-09-16 | 2025-07-16 | Lomond Therapeutics Inc | COMPOUNDS COMPRISING N-ARYLPYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC AGENTS |
| CN119462522A (zh) * | 2023-08-08 | 2025-02-18 | 浙江大学 | N2-3-氟-5-取代苯基-2-氨基嘧啶类衍生物、其制备方法及医药用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| ATE407678T1 (de) * | 2001-10-17 | 2008-09-15 | Boehringer Ingelheim Pharma | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| HRP20050089B1 (hr) | 2002-07-29 | 2015-06-19 | Rigel Pharmaceuticals | Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti |
| WO2004043386A2 (en) | 2002-11-08 | 2004-05-27 | Tolerrx, Inc. | Molecules preferentially associated with effector t cells and methods of their use |
| UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| JP4665760B2 (ja) | 2003-06-25 | 2011-04-06 | 日本電気株式会社 | 電子計算機、半導体集積回路、制御方法、プログラムの生成方法、及びプログラム |
| WO2005012294A1 (en) | 2003-07-30 | 2005-02-10 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| ATE506953T1 (de) * | 2003-08-07 | 2011-05-15 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
| CA2540543A1 (en) | 2003-10-09 | 2005-05-06 | Actelion Pharmaceuticals Ltd | Tetrahydropyridine derivatives |
| US20050164323A1 (en) | 2003-12-24 | 2005-07-28 | Wyeth | Methods of treating asthma |
| BRPI0509754A (pt) * | 2004-04-08 | 2007-10-16 | Novartis Ag | inibidores de proteìna quinase c para o tratamento de doenças auto-imunes e de rejeição a transplante |
| EP1883302A4 (en) * | 2005-05-03 | 2009-05-20 | Rigel Pharmaceuticals Inc | JAK KINASE HEMMER AND ITS USE |
| JP2010522765A (ja) | 2007-03-28 | 2010-07-08 | アレイ バイオファーマ、インコーポレイテッド | 受容体チロシンキナーゼとしてのイミダゾ［１，２−ａ］ピリジン化合物 |
| CN101903357A (zh) * | 2007-07-17 | 2010-12-01 | 里格尔药品股份有限公司 | 作为pkc抑制剂的环状胺取代的嘧啶二胺 |
| NZ603525A (en) * | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| JP6035238B2 (ja) * | 2010-07-21 | 2016-11-30 | ライジェル ファーマシューティカルズ， インコーポレイテッド | プロテインキナーゼｃ阻害剤およびその使用 |
-
2010
- 2010-01-21 JP JP2011546451A patent/JP5781943B2/ja not_active Expired - Fee Related
- 2010-01-21 EP EP10701773.3A patent/EP2389373B1/en not_active Not-in-force
- 2010-01-21 WO PCT/US2010/021662 patent/WO2010090875A1/en not_active Ceased
- 2010-01-21 ES ES10701773.3T patent/ES2635504T3/es active Active
- 2010-01-21 CA CA2749837A patent/CA2749837C/en active Active
- 2010-01-21 US US12/691,607 patent/US8377924B2/en not_active Expired - Fee Related
-
2012
- 2012-12-18 US US13/718,632 patent/US9149475B2/en not_active Expired - Fee Related
-
2015
- 2015-02-03 JP JP2015018931A patent/JP2015110629A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012515724A5 (https=) | ||
| US10995064B2 (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | |
| JP2008521831A5 (https=) | ||
| KR20090030347A (ko) | 신규 트리시클릭 스피로피페리딘 화합물, 이들의 합성 및 이들의 케모킨 수용체 활성의 조절제로서의 용도 | |
| JP2013518881A5 (https=) | ||
| JP2014523901A5 (https=) | ||
| JP2005526723A5 (https=) | ||
| JP2019508407A5 (https=) | ||
| JP2008521829A5 (https=) | ||
| NZ724602A (en) | Ror-gamma modulators and uses thereof | |
| JP2017527578A5 (https=) | ||
| CA2732806A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2012255002A5 (https=) | ||
| JP2012515209A5 (https=) | ||
| JP2017528506A5 (https=) | ||
| WO2007017093A1 (en) | Substituted 2-benzyloxy-benzoic acid amide derivatives | |
| JP2007522142A5 (https=) | ||
| RU2007130153A (ru) | Амидные производные | |
| CN101959855A (zh) | 氮杂环丁烷衍生化合物、其制备方法和其治疗用途 | |
| EP3036215A1 (en) | Amide derivatives as lysophosphatidic acid receptor antagonists | |
| JP2009510097A5 (https=) | ||
| JP2010526867A5 (https=) | ||
| WO2015186821A1 (ja) | ２－アシルアミノチアゾール誘導体またはその塩 | |
| RU2720678C2 (ru) | Ингибиторы гистондеацетилазы | |
| JP2008525419A (ja) | Ｈｉｖ−１逆転写酵素の非ヌクレオシド阻害剤 |